Myriad Genetics (MYGN)
Market Price (10/3/2026): $4.54 | Market Cap: $430.4 MilSector: Health Care | Industry: Life Sciences Tools & Services
Myriad Genetics (MYGN)
Market Price (10/3/2026): $4.54Market Cap: $430.4 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Key risksMYGN key risks include [1] persistent revenue declines and unprofitability, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Key risksMYGN key risks include [1] persistent revenue declines and unprofitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 10/2/2026
Myriad Genetics (MYGN) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Myriad Genetics missed fiscal Q2 2026 earnings expectations and significantly lowered its full-year fiscal 2026 revenue guidance.
On July 30, 2026, Myriad Genetics reported its fiscal Q2 2026 results (for the period ending June 30, 2026), with a GAAP EPS of -$0.46, missing analyst estimates by $0.19. Revenue for the quarter was $190.7 million, falling short of estimates by $15.33 million and representing an 11% year-over-year decline. The company also reduced its full-year fiscal 2026 revenue outlook to a range of $770 million to $790 million, down from its prior guidance of $860 million to $880 million, which was substantially below the consensus estimate of approximately $863.6 million. This news led to a sharp 47% decline in the stock price on July 31, 2026, closing at $2.86.
2. Weak performance in Prenatal Health testing and ongoing reimbursement pressure for hereditary cancer tests contributed to the reduced outlook.
The revised full-year fiscal 2026 guidance was primarily driven by weaker-than-expected Prenatal Health test volumes, which fell 9% in fiscal Q2 2026, and more cautious assumptions regarding revenue per test. Additionally, hereditary cancer testing revenue decreased by 13% in fiscal Q2 2026, despite an 8% increase in volume, due to lower reimbursement rates and unfavorable estimate changes. Myriad Genetics' management cited "payer-generated revenue-cycle friction," including increased prior-authorization requirements, more medical-record requests, and higher denial rates as contributing factors.
Show more
Myriad Genetics (MYGN) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Myriad Genetics missed fiscal Q2 2026 earnings expectations and significantly lowered its full-year fiscal 2026 revenue guidance.
On July 30, 2026, Myriad Genetics reported its fiscal Q2 2026 results (for the period ending June 30, 2026), with a GAAP EPS of -$0.46, missing analyst estimates by $0.19. Revenue for the quarter was $190.7 million, falling short of estimates by $15.33 million and representing an 11% year-over-year decline. The company also reduced its full-year fiscal 2026 revenue outlook to a range of $770 million to $790 million, down from its prior guidance of $860 million to $880 million, which was substantially below the consensus estimate of approximately $863.6 million. This news led to a sharp 47% decline in the stock price on July 31, 2026, closing at $2.86.
2. Weak performance in Prenatal Health testing and ongoing reimbursement pressure for hereditary cancer tests contributed to the reduced outlook.
The revised full-year fiscal 2026 guidance was primarily driven by weaker-than-expected Prenatal Health test volumes, which fell 9% in fiscal Q2 2026, and more cautious assumptions regarding revenue per test. Additionally, hereditary cancer testing revenue decreased by 13% in fiscal Q2 2026, despite an 8% increase in volume, due to lower reimbursement rates and unfavorable estimate changes. Myriad Genetics' management cited "payer-generated revenue-cycle friction," including increased prior-authorization requirements, more medical-record requests, and higher denial rates as contributing factors.
Show more
Updated on 10/2/2026
Myriad Genetics (MYGN) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Myriad Genetics missed fiscal Q2 2026 earnings expectations and significantly lowered its full-year fiscal 2026 revenue guidance.
On July 30, 2026, Myriad Genetics reported its fiscal Q2 2026 results (for the period ending June 30, 2026), with a GAAP EPS of -$0.46, missing analyst estimates by $0.19. Revenue for the quarter was $190.7 million, falling short of estimates by $15.33 million and representing an 11% year-over-year decline. The company also reduced its full-year fiscal 2026 revenue outlook to a range of $770 million to $790 million, down from its prior guidance of $860 million to $880 million, which was substantially below the consensus estimate of approximately $863.6 million. This news led to a sharp 47% decline in the stock price on July 31, 2026, closing at $2.86.
2. Weak performance in Prenatal Health testing and ongoing reimbursement pressure for hereditary cancer tests contributed to the reduced outlook.
The revised full-year fiscal 2026 guidance was primarily driven by weaker-than-expected Prenatal Health test volumes, which fell 9% in fiscal Q2 2026, and more cautious assumptions regarding revenue per test. Additionally, hereditary cancer testing revenue decreased by 13% in fiscal Q2 2026, despite an 8% increase in volume, due to lower reimbursement rates and unfavorable estimate changes. Myriad Genetics' management cited "payer-generated revenue-cycle friction," including increased prior-authorization requirements, more medical-record requests, and higher denial rates as contributing factors.
3. Multiple analyst downgrades and significant price target reductions reflected a loss of confidence.
Following the disappointing fiscal Q2 2026 results and lowered guidance, several Wall Street analysts downgraded Myriad Genetics' stock and cut their price targets. On September 1, 2026, Piper Sandler double-downgraded the stock from Overweight to Underweight and drastically reduced its price target from $5.45 to $2.00. TD Cowen also lowered its price target from $6.00 to $4.00 on July 31, 2026, maintaining a "hold" rating. Stephens cut its price target from $5.00 to $3.00 on August 18, 2026. The consensus among analysts has shifted to a "Reduce" rating, with an average 12-month price target of $3.12.
4. Concerns about the structural nature of the company's challenges and a perceived lack of strategic alternatives intensified investor skepticism.
Analysts from Piper Sandler highlighted that Myriad's challenges, as evidenced by its fiscal Q2 2026 results, appeared to be "structural and not temporary." The analyst also suggested that the company's decision not to divest assets after a strategic review indicated a lack of interest at acceptable valuations, concluding that divestiture might be the "most credible path to value" given the business model's inability to consistently grow or achieve profitability. This sentiment contributed to a perception of enduring operational difficulties and limited strategic options for improvement.
Show less
Myriad Genetics (MYGN) stock has lost about 20% since 6/30/2026 because of the following key factors:
1. Myriad Genetics missed fiscal Q2 2026 earnings expectations and significantly lowered its full-year fiscal 2026 revenue guidance.
On July 30, 2026, Myriad Genetics reported its fiscal Q2 2026 results (for the period ending June 30, 2026), with a GAAP EPS of -$0.46, missing analyst estimates by $0.19. Revenue for the quarter was $190.7 million, falling short of estimates by $15.33 million and representing an 11% year-over-year decline. The company also reduced its full-year fiscal 2026 revenue outlook to a range of $770 million to $790 million, down from its prior guidance of $860 million to $880 million, which was substantially below the consensus estimate of approximately $863.6 million. This news led to a sharp 47% decline in the stock price on July 31, 2026, closing at $2.86.
2. Weak performance in Prenatal Health testing and ongoing reimbursement pressure for hereditary cancer tests contributed to the reduced outlook.
The revised full-year fiscal 2026 guidance was primarily driven by weaker-than-expected Prenatal Health test volumes, which fell 9% in fiscal Q2 2026, and more cautious assumptions regarding revenue per test. Additionally, hereditary cancer testing revenue decreased by 13% in fiscal Q2 2026, despite an 8% increase in volume, due to lower reimbursement rates and unfavorable estimate changes. Myriad Genetics' management cited "payer-generated revenue-cycle friction," including increased prior-authorization requirements, more medical-record requests, and higher denial rates as contributing factors.
3. Multiple analyst downgrades and significant price target reductions reflected a loss of confidence.
Following the disappointing fiscal Q2 2026 results and lowered guidance, several Wall Street analysts downgraded Myriad Genetics' stock and cut their price targets. On September 1, 2026, Piper Sandler double-downgraded the stock from Overweight to Underweight and drastically reduced its price target from $5.45 to $2.00. TD Cowen also lowered its price target from $6.00 to $4.00 on July 31, 2026, maintaining a "hold" rating. Stephens cut its price target from $5.00 to $3.00 on August 18, 2026. The consensus among analysts has shifted to a "Reduce" rating, with an average 12-month price target of $3.12.
4. Concerns about the structural nature of the company's challenges and a perceived lack of strategic alternatives intensified investor skepticism.
Analysts from Piper Sandler highlighted that Myriad's challenges, as evidenced by its fiscal Q2 2026 results, appeared to be "structural and not temporary." The analyst also suggested that the company's decision not to divest assets after a strategic review indicated a lack of interest at acceptable valuations, concluding that divestiture might be the "most credible path to value" given the business model's inability to consistently grow or achieve profitability. This sentiment contributed to a perception of enduring operational difficulties and limited strategic options for improvement.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -28.9% change in MYGN stock from 6/30/2026 to 10/1/2026 was primarily driven by a -26.1% change in the company's P/S Multiple.| (LTM values as of) | 6302026 | 10012026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.71 | 4.06 | -28.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 829 | 807 | -2.7% |
| P/S Multiple | 0.6 | 0.5 | -26.1% |
| Shares Outstanding (Mil) | 94 | 95 | -1.2% |
| Cumulative Contribution | -28.9% |
Market Drivers
6/30/2026 to 10/1/2026| Return | Correlation | |
|---|---|---|
| MYGN | -28.9% | |
| Market (SPY) | 2.3% | 8.2% |
| Sector (XLV) | 4.8% | 14.6% |
Fundamental Drivers
The -9.8% change in MYGN stock from 3/31/2026 to 10/1/2026 was primarily driven by a -6.5% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 10012026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.50 | 4.06 | -9.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 824 | 807 | -2.2% |
| P/S Multiple | 0.5 | 0.5 | -6.5% |
| Shares Outstanding (Mil) | 94 | 95 | -1.4% |
| Cumulative Contribution | -9.8% |
Market Drivers
3/31/2026 to 10/1/2026| Return | Correlation | |
|---|---|---|
| MYGN | -9.8% | |
| Market (SPY) | 17.8% | 6.3% |
| Sector (XLV) | 13.9% | 18.5% |
Fundamental Drivers
The -43.8% change in MYGN stock from 9/30/2025 to 10/1/2026 was primarily driven by a -40.6% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 10012026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.23 | 4.06 | -43.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 833 | 807 | -3.2% |
| P/S Multiple | 0.8 | 0.5 | -40.6% |
| Shares Outstanding (Mil) | 92 | 95 | -2.4% |
| Cumulative Contribution | -43.8% |
Market Drivers
9/30/2025 to 10/1/2026| Return | Correlation | |
|---|---|---|
| MYGN | -43.8% | |
| Market (SPY) | 15.6% | 17.7% |
| Sector (XLV) | 21.0% | 19.1% |
Fundamental Drivers
The -74.7% change in MYGN stock from 9/30/2023 to 10/1/2026 was primarily driven by a -74.6% change in the company's P/S Multiple.| (LTM values as of) | 9302023 | 10012026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.04 | 4.06 | -74.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 699 | 807 | 15.4% |
| P/S Multiple | 1.9 | 0.5 | -74.6% |
| Shares Outstanding (Mil) | 82 | 95 | -13.8% |
| Cumulative Contribution | -74.7% |
Market Drivers
9/30/2023 to 10/1/2026| Return | Correlation | |
|---|---|---|
| MYGN | -74.7% | |
| Market (SPY) | 84.9% | 24.3% |
| Sector (XLV) | 35.2% | 21.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MYGN Return | 40% | -47% | 32% | -28% | -55% | -31% | -79% |
| Peers Return | 38% | -41% | 2% | 26% | 23% | 47% | 86% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 104% |
Monthly Win Rates [3] | |||||||
| MYGN Win Rate | 50% | 25% | 50% | 50% | 33% | 44% | |
| Peers Win Rate | 67% | 35% | 42% | 52% | 55% | 67% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| MYGN Max Drawdown | -34% | -48% | -41% | -54% | -74% | -57% | |
| Peers Max Drawdown | -31% | -53% | -37% | -24% | -25% | -26% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NTRA, LH, DGX, ILMN, FLGT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/2/2026 (YTD)
How Low Can It Go
| Event | MYGN | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -37.2% | -9.5% |
| % Gain to Breakeven | 59.2% | 10.5% |
| Time to Breakeven | 91 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.3% | -24.5% |
| % Gain to Breakeven | 70.3% | 32.4% |
| Time to Breakeven | 768 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.1% | -33.7% |
| % Gain to Breakeven | 104.4% | 50.9% |
| Time to Breakeven | 293 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -40.2% | -19.2% |
| % Gain to Breakeven | 67.3% | 23.8% |
| Time to Breakeven | 221 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -28.6% | -3.7% |
| % Gain to Breakeven | 40.1% | 3.9% |
| Time to Breakeven | 85 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -14.5% | -6.8% |
| % Gain to Breakeven | 17.0% | 7.3% |
| Time to Breakeven | 21 days | 15 days |
In The Past
Myriad Genetics's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MYGN | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -37.2% | -9.5% |
| % Gain to Breakeven | 59.2% | 10.5% |
| Time to Breakeven | 91 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.3% | -24.5% |
| % Gain to Breakeven | 70.3% | 32.4% |
| Time to Breakeven | 768 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -51.1% | -33.7% |
| % Gain to Breakeven | 104.4% | 50.9% |
| Time to Breakeven | 293 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -40.2% | -19.2% |
| % Gain to Breakeven | 67.3% | 23.8% |
| Time to Breakeven | 221 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -28.6% | -3.7% |
| % Gain to Breakeven | 40.1% | 3.9% |
| Time to Breakeven | 85 days | 6 days |
| 2013 Taper Tantrum | ||
| % Loss | -23.7% | -0.2% |
| % Gain to Breakeven | 31.0% | 0.2% |
| Time to Breakeven | 30 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -23.4% | -17.9% |
| % Gain to Breakeven | 30.6% | 21.8% |
| Time to Breakeven | 173 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -37.8% | -15.4% |
| % Gain to Breakeven | 60.9% | 18.2% |
| Time to Breakeven | 148 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -28.2% | -53.4% |
| % Gain to Breakeven | 39.3% | 114.4% |
| Time to Breakeven | 74 days | 1085 days |
In The Past
Myriad Genetics's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Myriad Genetics (MYGN)
Myriad Genetics, Inc. (MYGN) is a genetic testing and precision medicine company that develops and commercializes molecular diagnostic tests. The company's core business involves leveraging advanced DNA and RNA analysis to provide crucial insights for assessing disease risk, guiding treatment decisions, and determining disease prognosis. Myriad's offerings aim to empower both patients and healthcare providers with personalized genetic information across various medical disciplines.
Myriad's extensive product portfolio spans key therapeutic areas, including oncology, women's health, and mental health. In oncology, notable tests include MyRisk Hereditary Cancer Test for assessing cancer risks, BRACAnalysis CDx and MyChoice CDx as companion diagnostics for cancer treatment selection, and Prolaris and EndoPredict for prognostic insights into prostate and breast cancers. For women's health, the company offers prenatal screenings like Prequel Prenatal Screen for chromosomal disorders and Foresight Carrier Screen for assessing the risk of passing on recessive genetic conditions. A significant mental health product is GeneSight Psychotropic, which uses DNA genotyping to aid in selecting appropriate medications for conditions such as depression and anxiety.
The company primarily serves patients, typically through their healthcare providers, who require specialized genetic insights. Its diverse customer base includes individuals seeking hereditary cancer risk assessment, cancer patients requiring treatment guidance, prospective parents concerned about genetic conditions, and those with mental health disorders needing personalized medication approaches. Operating both domestically and internationally, Myriad Genetics aims to enhance patient care and outcomes by delivering precision diagnostic tools to these critical markets.
AI Analysis | Feedback
- A 23andMe for medical professionals, offering advanced genetic tests for critical health decisions in cancer, reproductive health, and mental well-being.
- Like Quest Diagnostics or LabCorp, but specialized in cutting-edge genetic and molecular diagnostic tests that provide precise insights for oncology, women's health, and mental health treatment.
AI Analysis | Feedback
- MyRisk Hereditary Cancer Test: A DNA sequencing test for assessing an individual's risk for hereditary cancers.
- BRACAnalysis CDx Germline Companion Diagnostic Test: Helps determine therapy for patients with certain metastatic cancers who have specific germline BRCA variants.
- MyChoice CDx Companion Diagnostic Test: A tumor test that identifies homologous recombination deficiency status in patients with ovarian cancer.
- Prolaris Prostate Cancer Prognostic Test: Assesses the aggressiveness of prostate cancer through RNA expression tumor analysis.
- EndoPredict Breast Cancer Prognostic Test: An RNA expression test for evaluating the aggressiveness of breast cancer.
- Precise Tumor: A comprehensive solution designed for precision oncology.
- Prequel Prenatal Screen: A non-invasive prenatal screening test performed on maternal blood to screen for severe chromosomal disorders in a fetus.
- Foresight Carrier Screen: A prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring.
- GeneSight Psychotropic Mental Health Medication Test: A DNA genotyping test that aids in psychotropic drug selection for patients with various mental health conditions.
AI Analysis | Feedback
Myriad Genetics (MYGN) primarily sells its genetic testing and precision medicine services for the benefit of individual patients. These services are typically ordered by healthcare professionals for their patients. Based on its diverse range of diagnostic tests and their applications, Myriad Genetics serves the following three primary categories of customers:
- Oncology Patients: Individuals who require genetic testing for various cancer-related needs. This includes assessing the risk for hereditary cancers (e.g., with MyRisk), guiding therapy for patients with metastatic breast, ovarian, pancreatic, or prostate cancer (e.g., with BRACAnalysis CDx or MyChoice CDx), and determining the aggressiveness of prostate or breast cancer (e.g., with Prolaris or EndoPredict).
- Women's Health Patients: Individuals in different stages of family planning or pregnancy. This category includes expectant mothers seeking non-invasive prenatal screening for chromosomal disorders in a fetus (Prequel Prenatal Screen) and future parents assessing their risk of passing on recessive genetic conditions to their offspring (Foresight Carrier Screen).
- Mental Health Patients: Individuals suffering from mental health conditions such as depression, anxiety, or ADHD. For these patients, Myriad offers genetic testing (e.g., GeneSight Psychotropic Mental Health Medication Test) to aid healthcare providers in selecting more appropriate psychotropic medications based on an individual's genetic profile.
AI Analysis | Feedback
Illumina, Inc. (ILMN)
AI Analysis | Feedback
Sam Raha, President and Chief Executive Officer
Sam Raha has served as President and Chief Executive Officer and a member of the board of directors at Myriad Genetics since April 2025. He joined Myriad in December 2023 as Chief Operating Officer. Prior to Myriad, he was President of Agilent's Diagnostics and Genomics Group and also served as Vice President of Global Marketing at Illumina. He holds an MBA from Santa Clara University and a bachelor's degree in molecular and cell biology from the University of California, Berkeley.
Ben Wheeler, Chief Financial Officer
Ben Wheeler was promoted to Chief Financial Officer, effective August 2025. He joined Myriad in December 2011 as assistant controller and has progressed through various financial leadership roles, including vice president, corporate controller; senior vice president, accounting; senior vice president, finance & treasury; and chief financial officer, operations. Before joining Myriad, he worked as an auditor for Ernst & Young. Mr. Wheeler holds both master's and bachelor's degrees in accounting from Brigham Young University and is a Certified Public Accountant.
Mark Verratti, Chief Operating Officer
Mark Verratti has served as Chief Operating Officer at Myriad Genetics since April 2025. Prior to this role, he was the Chief Commercial Officer. He joined Myriad Genetics in 2017 as President of Myriad's Mental Health business, which includes the GeneSight® pharmacogenomics test.
Brian Donnelly, Chief Commercial Officer
Brian Donnelly was appointed Chief Commercial Officer at Myriad Genetics in May 2025. In this role, he oversees global commercial strategy and execution. He brings over 20 years of leadership experience in diagnostics, genomics, and consumer health, having held prior roles at Ancestry, Amazon, Illumina, and GlaxoSmithKline. Mr. Donnelly holds an MBA and a J.D. from Rutgers University.
Dr. Patrick Burke, Executive Vice President of Innovation and Strategic Partnerships
Dr. Patrick Burke was promoted to Executive Vice President of Strategy and Innovation in May 2021. He is responsible for corporate development, Myriad's companion diagnostics business, digital strategy, and partnerships with large health systems and healthcare providers. Dr. Burke joined Myriad in 2001 and has more than 20 years of experience in the precision medicine and pharmaceutical industries.
AI Analysis | Feedback
Key Risks to Myriad Genetics (MYGN)
- Intellectual Property Challenges and Expirations: Myriad Genetics heavily relies on its proprietary tests and methods, which are protected by patents. The expiration of key patents, or successful legal challenges to existing intellectual property rights, could open the door for increased competition from other companies offering similar genetic tests. This could lead to significant pricing pressure and erosion of market share, similar to the concept of a "patent cliff" in the pharmaceutical industry.
- Reimbursement and Payer Coverage Changes: The success of Myriad's genetic tests is highly dependent on favorable reimbursement policies and coverage decisions by governmental and commercial payers. Changes in medical policy, decreases in reimbursement rates, or a reduction in covered indications for its molecular diagnostic tests could significantly impact the company's revenue and profitability.
- Rapid Technological Advancements and Intense Competition: The genetic testing and precision medicine landscape is characterized by rapid technological innovation and a highly competitive environment. New sequencing technologies, advanced bioinformatics, and novel diagnostic approaches are continuously emerging. Myriad faces the ongoing risk that competitors could develop superior, more cost-effective, or more comprehensive tests, potentially rendering Myriad's current offerings less competitive or even obsolete if the company does not continually innovate and adapt.
AI Analysis | Feedback
null
AI Analysis | Feedback
Myriad Genetics, Inc. (MYGN) operates in several key precision medicine markets, developing and commercializing genetic tests for oncology, women's health, and mental health applications. The addressable markets for its main products and services are significant, both in the U.S. and globally.
Oncology Portfolio (MyRisk Hereditary Cancer Test, BRACAnalysis CDx, MyChoice CDx, Prolaris Prostate Cancer Prognostic Test, EndoPredict Breast Cancer Prognostic Test, Precise Tumor)
- Hereditary Cancer Testing Market (relevant to MyRisk Hereditary Cancer Test): The global hereditary cancer testing market was estimated at approximately USD 4.67 billion in 2024 and is projected to grow to about USD 14.45 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 13.76% from 2025 to 2033. In the United States, this market was valued at approximately USD 1.93 billion in 2024 and is projected to reach USD 5.76 billion by 2033, demonstrating a CAGR of 13.3%.
- Precision Oncology Market (relevant to Precise Tumor, BRACAnalysis CDx, MyChoice CDx, and other oncology tests): The global precision oncology market was valued at approximately USD 115.25 billion in 2024 and is expected to reach around USD 250.43 billion by 2034, growing at a CAGR of 8.07% from 2025 to 2034. The diagnostics segment within the precision oncology market is anticipated to exhibit significant growth. For the U.S. alone, the precision oncology market size was estimated at USD 38.9 billion in 2024 and is expected to reach about USD 84.52 billion by 2034, with a CAGR of 7.3%.
- Breast Cancer Diagnostics Market (relevant to EndoPredict Breast Cancer Prognostic Test, MyChoice CDx, and BRACAnalysis CDx): The global breast cancer diagnostics market was estimated at approximately USD 5.86 billion in 2025 and is projected to reach USD 11.36 billion by 2033, growing at a CAGR of 8.8% from 2026 to 2033.
- Prostate Cancer Testing Market (relevant to Prolaris Prostate Cancer Prognostic Test): The U.S. prostate cancer biomarkers market was valued at approximately USD 1.7 billion in 2024. The U.S. prostate cancer testing market is anticipated to reach USD 1,901.6 million in 2030 from USD 544.1 million in 2021, at a CAGR of 14.7% during the forecast period 2022-2030. The broader U.S. prostate cancer diagnostics market is expected to reach US$ 4,653.5 million by 2030, with a CAGR of 5.3% from 2024 to 2030.
Women's Health Portfolio (Prequel Prenatal Screen, Foresight Carrier Screen)
- Non-Invasive Prenatal Screening (NIPS) / Non-Invasive Prenatal Testing (NIPT) Market (relevant to Prequel Prenatal Screen): The global NIPS/NIPT market was estimated at approximately US$ 3.68 billion in 2025 and is projected to reach US$ 5.91 billion by 2032, with a CAGR of 7.1% from 2026 to 2032. In the United States, this market generated approximately US$ 1.52 billion in 2023 and is expected to reach US$ 2.78 billion by 2030, growing at a CAGR of 9.1% from 2024 to 2030.
- Carrier Screening Market (relevant to Foresight Carrier Screen): The global carrier screening market was valued at approximately USD 1.70 billion in 2025 and is projected to grow to USD 3.08 billion by 2034, exhibiting a CAGR of 6.4% during the forecast period. In the United States, the carrier screening market was valued at approximately USD 740.92 million in 2024 and is expected to reach USD 842.95 million in 2025.
Mental Health Portfolio (GeneSight Psychotropic Mental Health Medication Test)
- Pharmacogenomics in Psychiatry/Depression Market (relevant to GeneSight Psychotropic Mental Health Medication Test): The global pharmacogenetics testing in psychiatry/depression market size was valued at approximately USD 1.34 billion in 2024 and is expected to reach USD 2.97 billion by 2032, at a CAGR of 10.4%. The U.S. pharmacogenetics testing in psychiatry/depression market held the largest revenue share within North America in 2024, accounting for 81.0% of the market. Myriad Genetics previously estimated the global market for GeneSight testing to be greater than $4 billion based on current and future indications.
AI Analysis | Feedback
Myriad Genetics (MYGN) anticipates several key drivers for future revenue growth over the next 2-3 years, stemming from strong performance in core areas, new product introductions, and strategic initiatives.
Here are 3-5 expected drivers of future revenue growth:
* Sustained Volume Growth in Core Oncology and Mental Health Tests: Myriad Genetics expects continued strong test volume increases in its core oncology and mental health franchises. Notably, tests like MyRisk Hereditary Cancer Test, GeneSight Psychotropic Mental Health Medication Test, and Prolaris Prostate Cancer Prognostic Test have demonstrated consistent year-over-year volume growth and are projected to continue gaining market share.
* Launch of New and Expanded Products: The company plans to introduce multiple new and enhanced products in the coming years. Key launches anticipated in 2026 include an expanded MyRisk panel, an AI-enhanced Prolaris prostate cancer test, and Precise MRD for breast cancer. Additionally, new prenatal tests, such as FirstGene, are expected to enrich the product portfolio and drive future revenue. Myriad is also integrating Precise Tumor and Precise Liquid into its Precise Oncology Solutions platform.
* Reacceleration of the Prenatal Testing Segment: Following past order management disruptions, Myriad Genetics is focused on rebuilding its prenatal segment and expects growth to reaccelerate in the coming quarters. The introduction of new prenatal tests like FirstGene is a part of this strategy.
* Strategic Collaborations and Technology Enhancements: Myriad is engaging in strategic collaborations and integrating advanced technologies to enhance its offerings. An example is the partnership with Clairity and MagView to integrate Clairity's AI system with Myriad's MyRisk test to improve breast cancer risk assessment tools. This focus on technology and strategic partnerships is expected to bolster its competitive edge and drive revenue.
AI Analysis | Feedback
Share Repurchases
- Myriad Genetics spent $0 on share buybacks in Q4 2019 and Q2 2026, indicating no significant share repurchases in recent years.
Share Issuance
- In November 2023, Myriad Genetics announced an upsized public offering of 6,470,588 shares of common stock at $17.00 per share, generating approximately $110 million in gross proceeds.
- As of March 4, 2026, Myriad Genetics registered a shelf to offer up to $200 million of common stock, preferred stock, depositary shares, debt securities, and/or warrants, providing authorization for future capital raises.
- The number of shares outstanding increased from 78 million at the end of 2021 to 93.5 million as of March 13, 2026, reflecting recent share issuances.
Inbound Investments
- In July 2025, the company secured a new $200 million term loan facility to enhance financial flexibility and support growth initiatives.
- In January 2025, Myriad Genetics announced a five-year strategic alliance with The University of Texas MD Anderson Cancer Center to accelerate the clinical evaluation and development of its Precise MRD assay.
- In September 2025, Myriad Genetics entered a strategic collaboration with SOPHiA GENETICS to develop and provide a global liquid biopsy companion diagnostic (CDx) test.
Outbound Investments
- The most recent acquisition by Myriad Genetics was Gateway Genomics in November 2022 for $67.5 million, which develops a fetal development diagnostic genetic test.
- In February 2024, Myriad Genetics acquired select assets, including the Precise™ Tumor Test, the Precise Liquid Test, and a CLIA-certified laboratory in St. George, Utah, from Intermountain Health's Intermountain Precision Genomics (IPG) laboratory business.
Capital Expenditures
- Myriad Genetics invested $18.8 million in capital expenditures in Q4 2023.
- Capital expenditures and capitalization of internal use software costs totaled $6.0 million in Q4 2025 and $6.9 million in Q2 2025.
- The company forecasts annual capital expenditures to be between $20 million and $30 million, focusing on supporting its diagnostic testing capabilities, new product launches, and digital integration.
Peer Outperformance in Life Sciences Tools & Services
nullShare of Life Sciences Tools & Services constituents that MYGN has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
—
insufficient peer history
3Y
—
insufficient peer history
5Y
—
insufficient peer history
null
null
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 273.07 |
| Mkt Cap | 25.8 |
| Rev LTM | 11,560 |
| Op Inc LTM | 1,629 |
| FCF LTM | 1,155 |
| FCF 3Y Avg | 1,090 |
| CFO LTM | 1,638 |
| CFO 3Y Avg | 1,573 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.4% |
| Rev Chg 3Y Avg | 6.5% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 10.5% |
| Op Inc Chg 3Y Avg | 11.6% |
| Op Mgn LTM | 14.1% |
| Op Mgn 3Y Avg | 13.4% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 16.5% |
| CFO/Rev 3Y Avg | 15.3% |
| FCF/Rev LTM | 11.7% |
| FCF/Rev 3Y Avg | 10.9% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Hereditary Cancer | 372 | 364 | 328 | 306 | 316 |
| Prenatal Health | 186 | 177 | 151 | 116 | 107 |
| Mental Health | 144 | 170 | 138 | 128 | 94 |
| Tumor Profiling | 122 | 126 | 136 | 129 | 121 |
| Autoimmune | 0 | 28 | |||
| Other | 0 | ||||
| Other revenue | 24 | ||||
| Total | 825 | 838 | 753 | 678 | 691 |
| $ Mil | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|
| Diagnostics | -82 | 133 | 139 | 131 |
| Other | -149 | -126 | -21 | -82 |
| Total | -232 | 8 | 119 | 49 |
| $ Mil | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|
| Cash, cash equivalents, and marketable investment | 255 | 192 | 211 | 199 |
| Diagnostics | 1,003 | 1,216 | 840 | 901 |
| Other | 147 | 155 | 122 | 124 |
| Total | 1,405 | 1,563 | 1,174 | 1,224 |
Price Behavior
Price Behavior
| Market Price | $4.06 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 10/06/1995 | |
| Distance from 52W High | -50.4% | |
| 50 Days | 200 Days | |
| DMA Price | $3.68 | $4.78 |
| DMA Trend | down | down |
| Distance from DMA | 10.2% | -15.1% |
| 3M | 1YR | |
| Volatility | 110.3% | 78.8% |
| Downside Capture | 99.93 | 123.91 |
| Upside Capture | -122.50 | 27.88 |
| Correlation (SPY) | 8.8% | 17.7% |
MYGN Betas & Captures as of 9/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.83 | 1.78 | 0.84 | 0.48 | 1.08 | 1.17 |
| Up Beta | 2.68 | 1.78 | 2.83 | 1.02 | 1.08 | 1.00 |
| Down Beta | -2.34 | -1.70 | 0.55 | 0.66 | 1.54 | 1.17 |
| Up Capture | 266% | 382% | -77% | -5% | 32% | 55% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 14 | 24 | 33 | 68 | 121 | 358 |
| Down Capture | -297% | -17% | 71% | 5% | 115% | 110% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 7 | 17 | 30 | 57 | 128 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MYGN | |
|---|---|---|---|---|
| MYGN | -44.0% | 78.9% | -0.32 | - |
| Sector ETF (XLV) | 21.0% | 16.0% | 1.00 | 19.1% |
| Equity (SPY) | 15.7% | 13.0% | 0.85 | 17.7% |
| Gold (GLD) | 7.7% | 29.6% | 0.25 | 7.4% |
| Commodities (DBC) | 45.6% | 20.8% | 1.69 | -1.8% |
| Real Estate (VNQ) | 1.2% | 13.6% | -0.16 | 13.1% |
| Bitcoin (BTCUSD) | -25.7% | 44.5% | -0.54 | 18.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MYGN | |
|---|---|---|---|---|
| MYGN | -34.1% | 66.3% | -0.34 | - |
| Sector ETF (XLV) | 6.3% | 15.2% | 0.23 | 27.0% |
| Equity (SPY) | 13.0% | 17.2% | 0.57 | 33.1% |
| Gold (GLD) | 18.6% | 18.9% | 0.80 | 11.5% |
| Commodities (DBC) | 10.6% | 19.6% | 0.42 | 5.5% |
| Real Estate (VNQ) | 0.4% | 18.9% | -0.08 | 27.9% |
| Bitcoin (BTCUSD) | 13.6% | 52.3% | 0.43 | 16.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MYGN | |
|---|---|---|---|---|
| MYGN | -14.5% | 66.6% | 0.07 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.51 | 29.9% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 34.1% |
| Gold (GLD) | 11.6% | 16.4% | 0.58 | 8.1% |
| Commodities (DBC) | 8.4% | 18.1% | 0.38 | 10.2% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.17 | 28.1% |
| Bitcoin (BTCUSD) | 64.2% | 66.2% | 1.04 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/16/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | -46.7% | -40.8% | -41.2% |
| 5/5/2026 | -18.3% | -19.1% | -6.8% |
| 2/23/2026 | 1.1% | 14.4% | 5.3% |
| 11/3/2025 | -21.0% | -20.8% | -10.4% |
| 8/5/2025 | 46.5% | 55.8% | 75.5% |
| 5/6/2025 | -41.3% | -43.5% | -32.3% |
| 2/24/2025 | -14.8% | -24.6% | -29.4% |
| 11/7/2024 | -1.5% | -11.3% | -15.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 10 | 10 |
| # Negative | 12 | 14 | 14 |
| Median Positive | 7.9% | 11.5% | 11.4% |
| Median Negative | -11.4% | -19.0% | -12.5% |
| Max Positive | 46.5% | 55.8% | 75.5% |
| Max Negative | -46.7% | -43.5% | -41.2% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/30/2026 | -46.7% | -40.8% | -41.2% |
| 5/5/2026 | -18.3% | -19.1% | -6.8% |
| 2/23/2026 | 1.1% | 14.4% | 5.3% |
| 11/3/2025 | -21.0% | -20.8% | -10.4% |
| 8/5/2025 | 46.5% | 55.8% | 75.5% |
| 5/6/2025 | -41.3% | -43.5% | -32.3% |
| 2/24/2025 | -14.8% | -24.6% | -29.4% |
| 11/7/2024 | -1.5% | -11.3% | -15.8% |
| 8/6/2024 | 2.6% | 8.6% | 6.5% |
| 5/7/2024 | 21.1% | 28.2% | 12.7% |
| 2/27/2024 | -8.0% | -5.4% | -8.9% |
| 11/6/2023 | 8.7% | 0.9% | 10.0% |
| 8/3/2023 | -7.0% | -19.6% | -13.2% |
| 5/3/2023 | -3.7% | -18.8% | 7.0% |
| 2/28/2023 | 13.2% | 14.7% | 23.3% |
| 11/1/2022 | -15.6% | -21.5% | -2.3% |
| 8/4/2022 | 5.7% | 5.9% | -13.7% |
| 5/5/2022 | -1.1% | -9.2% | -11.7% |
| 2/24/2022 | 7.0% | -1.0% | 6.4% |
| 11/2/2021 | -1.3% | 2.0% | -20.2% |
| 8/3/2021 | 14.2% | 8.4% | 15.9% |
| 5/3/2021 | 4.0% | -14.1% | -7.3% |
| 2/23/2021 | 3.7% | -1.4% | -3.1% |
| 11/9/2020 | 19.0% | 17.2% | 29.4% |
| SUMMARY STATS | |||
| # Positive | 12 | 10 | 10 |
| # Negative | 12 | 14 | 14 |
| Median Positive | 7.9% | 11.5% | 11.4% |
| Median Negative | -11.4% | -19.0% | -12.5% |
| Max Positive | 46.5% | 55.8% | 75.5% |
| Max Negative | -46.7% | -43.5% | -41.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/31/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/31/2026 | 10-Q |
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/04/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 03/16/2021 | 10-KT |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-K |
| 03/31/2020 | 05/06/2020 | 10-Q |
| 12/31/2019 | 02/07/2020 | 10-Q |
| 09/30/2019 | 11/06/2019 | 10-Q |
Recent Forward Guidance
Updated 9/28/2026Latest: Q2 2026 Earnings Reported 7/30/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 770.00 Mil | 780.00 Mil | 790.00 Mil | -10.3% | Lowered | Guidance: 870.00 Mil for 2026 | |
| 2026 Gross Profit | Calculated | 508.20 Mil | 518.70 Mil | 529.30 Mil | Rev x Gross Margin | |||
| 2026 Adjusted Gross Margin | Reported | 66.0% | 66.5% | 67.0% | -2.0% | Lowered | Guidance: 68.5% for 2026 | |
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 860.00 Mil | 870.00 Mil | 880.00 Mil | 0 | Affirmed | Guidance: 870.00 Mil for 2026 | |
| 2026 Gross Profit | Calculated | 584.80 Mil | 595.95 Mil | 607.20 Mil | Rev x Gross Margin | |||
| 2026 Adjusted Gross Margin | Reported | 68.0% | 68.5% | 69.0% | 0 | Affirmed | Guidance: 68.5% for 2026 | |
| 2026 Adjusted EBITDA | Reported | 37.00 Mil | 43.00 Mil | 49.00 Mil | 0 | Affirmed | Guidance: 43.00 Mil for 2026 | |
Q4 2025 Earnings Reported 2/23/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | Reported | 200.00 Mil | 201.50 Mil | 203.00 Mil | ||||
| Q1 2026 Revenue Growth | Reported | 2.0% | 3.0% | 4.0% | ||||
| 2026 Revenue | Reported | 860.00 Mil | 870.00 Mil | 880.00 Mil | 5.7% | Higher New | Actual: 823.00 Mil for 2025 | |
| 2026 Adjusted Gross Margin | Reported | 68.0% | 68.5% | 69.0% | -1.2% | Lower New | Actual: 69.75% for 2025 | |
| 2026 Adjusted EBITDA | Reported | 37.00 Mil | 43.00 Mil | 49.00 Mil | 43.3% | Higher New | Actual: 30.00 Mil for 2025 | |
Q3 2025 Earnings Reported 11/3/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | Reported | 818.00 Mil | 823.00 Mil | 828.00 Mil | 0 | Affirmed | Guidance: 823.00 Mil for 2025 | |
| 2025 Gross Profit | Calculated | 568.51 Mil | 574.04 Mil | 579.60 Mil | Rev x Gross Margin | |||
| 2025 Gross Margin % | Reported | 69.5% | 69.75% | 70.0% | 0 | Affirmed | Guidance: 69.75% for 2025 | |
| 2025 Adjusted Operating Expenses | Reported | 562.00 Mil | 565.00 Mil | 568.00 Mil | 0 | Affirmed | Guidance: 565.00 Mil for 2025 | |
| 2025 Operating Income | Calculated | 0.51 Mil | 9.04 Mil | 17.60 Mil | Rev x Gross Margin - Opex | |||
| 2025 Operating Margin | Calculated | 0.06% | 1.1% | 2.13% | Implied by guided Rev/GM/Opex | |||
| 2025 Adjusted EBITDA | Reported | 27.00 Mil | 30.00 Mil | 33.00 Mil | 0 | Affirmed | Guidance: 30.00 Mil for 2025 | |
| 2025 Adjusted EPS | Reported | -0.02 | 0 | 0.02 | Affirmed | Guidance: 0 for 2025 | ||
Insider Activity
Updated 9/22/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kumar, Rashmi | Direct | Sell | 6092026 | 4.46 | 15,000 | 66,843 | 765,972 | Form | |
| 2 | Bisaro, Paul | Direct | Buy | 5142026 | 3.69 | 7,500 | 27,638 | 359,070 | Form | |
| 3 | Raha, Samraat S | President and CEO | Direct | Buy | 3092026 | 5.00 | 40,000 | 199,844 | 2,463,597 | Form |
| 4 | Phanstiel, S. Louise | Direct | Buy | 2272026 | 4.66 | 48,000 | 223,728 | 1,314,174 | Form | |
| 5 | Phanstiel, S. Louise | Direct | Buy | 2272026 | 4.80 | 50,407 | 242,105 | 1,123,667 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kumar, Rashmi | Direct | Sell | 6092026 | 4.46 | 15,000 | 66,843 | 765,972 | Form | |
| 2 | Bisaro, Paul | Direct | Buy | 5142026 | 3.69 | 7,500 | 27,638 | 359,070 | Form | |
| 3 | Raha, Samraat S | President and CEO | Direct | Buy | 3092026 | 5.00 | 40,000 | 199,844 | 2,463,597 | Form |
| 4 | Phanstiel, S. Louise | Direct | Buy | 2272026 | 4.66 | 48,000 | 223,728 | 1,314,174 | Form | |
| 5 | Phanstiel, S. Louise | Direct | Buy | 2272026 | 4.80 | 50,407 | 242,105 | 1,123,667 | Form | |
| 6 | Phanstiel, S. Louise | Direct | Buy | 2272026 | 4.74 | 6,100 | 28,890 | 869,264 | Form |
Investor Activity (13F)
Updated Oct 3, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 10/1/2026